JZJia-Geng Zhu

Jia-Geng Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jia-Geng Zhu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Hong-Fei Wu

    Department of Urology, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, 210019, China

    2 shared publications
  • Jianzhong Lin

    Jiangsu Taizhou People's Hospital

    2 shared publications
  • Alex Armstrong

    Department of Pharmacology, University of Manchester, Manchester, England

    1 shared publication
  • Cheng-Yang Zhang

    Department of Central Laboratory, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, 210019, China

    1 shared publication
  • Gang-Yi Zhu

    Department of Central Laboratory, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, 210019, China

    1 shared publication
  • Hong-Bo Yu

    Department of Urology, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, 210019, China

    1 shared publication

Latest Publications

  • FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy

    by Jian-Zhong Lin, Wei-Wan Wang, Ting-Ting Hu, Gang-Yi Zhu, Li-Nan Li, Cheng-Yang Zhang, Zheng Xu, Hong-Bo Yu, Hong-Fei Wu, Jia-Geng Zhu


  • Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer

    by Jian‑Zhong Lin, Irbaz Hameed, Zhen Xu, Yang Yu, Zhi‑Yun Ren, Jia‑Geng Zhu

    Resistance to docetaxel is a major clinical problem in castration-resistant prostate cancer (CRPC). We have previously reported that the combined inhibition of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) led to an increased antitumor activity of docetaxel in CRPC. In the present study, we explored the efficacy of the combination of EGFR inhibition (by gefitinib) and COX-2 inhibition (by celecoxib) as a potential treatment for docetaxel-resistant CRPC. We established two docetaxel-resistant prostate cancer cell lines, PC3/DR and DU145/DR, by culturing PC3 and DU145 cells in docetaxel in a dose-escalating manner. The EGFR and COX-2 protein expression levels were determined. The effects of gefitinib and celecoxib on cell proliferation, apoptosis and invasion in vitro and in vivo were evaluated. In vitro changes in Bcl-2, FOXM1 and ABCB1 expression were analyzed. The expression of Ki-67 and cleaved-caspase-3 was also examined in DU145/DR tumor tissue.The enhanced expression of EGFR and COX-2 was observed in docetaxel-resistant CRPC relative to the parental cell lines. MTT, clone formation and fluorescence-activated cell sorting (FACS) analyses demonstrated that gefitinib and celecoxib in combination decreased cell viability and enhanced the rate of apoptosis when compared with either drug used alone. Additionally, the combination treatment was superior in inhibiting cell invasion and induced significant decreases in Bcl-2, FOXM1 and ABCB1 expression levels. Furthermore, the gefitinib-celecoxib combination inhibited DU145/DR tumor growth to a greater extent than either treatment used individually. The expression of Ki-67 was reduced, whereas cleaved-caspase-3 protein expression was increased in the tumors from the combination therapy group. In conclusion, the combined inhibition of EGFR and COX-2 by gefitinib and celecoxib may overcome docetaxel resistance in human CRPC. These findings provided a molecular basis for the clinical application of a novel combination therapy for docetaxel-resistant CRPC.


  • Open Access

    Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer

    by Jian-Zhong Lin, Zeng-Jun Wang, Wei De, Ming Zheng, Wei-Zhang Xu, Hong-Fei Wu, Alex Armstrong, Jia-Geng Zhu

    Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer